单味中药及提取物治疗桥本甲状腺炎的研究进展

Research Progress on Single Chinese Medicine and Extracts in Treatment of Hashimoto’s Thyroiditis

桥本甲状腺炎(hashimoto’s thyroiditis, HT)是一种以自身甲状腺细胞为抗原的器官特异性自身免疫疾病,过程中淋巴细胞浸润,自身抗体TPOAb、TGAb水平升高,伴有甲状腺肿大、损伤、功能异常,是甲状腺最常见的疾病之一,西医治疗多采用甲状腺激素替代治疗,患者可能终身服药,严重影响患者生活质量和健康。近年来,单味中药及提取物在治疗HT方面取得较大进展,临床疗效显著,且不良反应小。本文综述了近年来有关单味中药及提取物在治疗HT方面的研究进展及机制,为临床开发新型治疗药物提供理论依据。

Hashimoto’s thyroiditis (HT) is an organ-specific autoimmune disease that uses its own thyroid cells as antigens, with lymphocyte infiltration in the process and elevated levels of autoantibodies TPOAb and TGAb, accompanied by thyroid enlargement, damage, and functional abnormalities, and it is one of the most common disorders of the thyroid gland, and western medical treatment is mostly thyroid hormone. Western medical treatment mostly uses thyroid hormone replacement therapy, and patients may take medication for life, which seriously affects their quality of life and health. In recent years, single-flavored Chinese medicines and extracts have made great progress in the treatment of HT, with remarkable clinical efficacy and small adverse effects. In this paper, we re-view the research progress and mechanism of single-flavored Chinese medicines and extracts in the treatment of HT in recent years, in order to provide a theoretical basis for the clinical development of new therapeutic drugs.